Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right.

Teva's stock has more than doubled over the past 12 months, with 12 of 13 analysts surveyed by S&P Global in May rating it a buy or strong buy and a consensus target implying about 11% upside. Branded-drug sales remain strong, led by Austedo, which rose 41% year over year to $578 million, while financial leverage improved to 67% as of March 31, 2026. Key upside catalysts include cost savings of roughly $470 million this year and a pending FDA decision on TEV-'749, though litigation and generic pricing pressure remain risks.

Analysis

TEVA is transitioning from balance-sheet repair to earnings-quality re-rating, which usually matters more to the market than headline growth. The second-order effect is that every incremental dollar of branded revenue now flows into a cleaner equity story because leverage has been reduced enough to lower the probability of a forced capital action; that can sustain multiple expansion even if generics remain structurally weak.

The real catalyst path is binary but underappreciated: a favorable regulatory readout on the injectable schizophrenia asset would validate management’s ability to replace legacy cash flows with higher-quality specialty revenue. If that happens, the market may begin underwriting TEVA less like a distressed turnaround and more like a de-risked specialty pharma platform, which can support a re-rating into the mid-teens forward multiple over 6-12 months. The flip side is that any delay or clinical/regulatory disappointment would likely hit harder now because expectations have shifted from survival to execution.

Consensus may still be underestimating how much of the stock’s upside is now tied to capital structure optics rather than pure operating momentum. As debt comes down, the equity gets more convex to modest earnings beats and less fragile to modest misses, but that also means the next leg is likely slower and more event-driven than the last 100% move. In other words, the easy money from de-stressing may already be largely captured; what remains is catalyst-dependent and more vulnerable to litigation or pricing headlines over the next 1-2 quarters.

Key Decisions for Investors

• Maintain a tactical long TEVA only into the FDA decision window over the next 3-6 months; use tight downside controls because the stock has likely already priced in much of the de-risking.
• Prefer a call spread in TEVA over outright stock ownership: upside is tied to one catalyst, while time decay is manageable if the event lands within the expected window.
• Pair long TEVA / short a diversified healthcare basket or a generic-heavy peer over 6-9 months to isolate the specialty-pipeline re-rating from sector beta and generic pricing pressure.
• If TEVA rallies another 10-15% before the catalyst, trim into strength and roll exposure forward only on confirmation, since the risk/reward shifts from re-rating to execution risk.
• Avoid chasing SPGI or EVR on this story; their relevance is informational, not economic. The tradeable expression is TEVA event risk, not the research ecosystem around it.